A Phase 2 Randomized Double-Blind, Parallel, Adaptive-Design, Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR with NRCT-202XR Compared to NRCT-202XR Alone in Subjects with Attention-Deficit/Hyperactivity Disorder
Latest Information Update: 26 Nov 2024
Price :
$35 *
At a glance
- Drugs NRCT 202 XR (Primary) ; NRCT-101SR (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Sponsors Neurocentria
- 21 Nov 2024 Status changed from not yet recruiting to recruiting.
- 07 Nov 2024 New trial record